SAB Biotherapeutics Discontinues P-III (ACTIV-2) Trial of SAB-185 for the Treatment of COVID-19
Shots:
- The NIH discontinues an enrolment in the P-III (ACTIV-2) trial of SAB-185 in patients with COVID-19 at higher risk for progression to hospitalization
- The discontinuation is due to a reduction in low Omicron-related COVID-19 hospitalization & death rates while the therapy has previously met the pre-specified safety & efficacy criteria & the study can be stopped for reasons of operational futility, following the recommendation of DSMB
- The company is planning for future programs of SAB-185 including targeted applications. SAB-185 is a targeted, highly potent, fully human polyclonal Abs & demonstrated neutralization of multiple SARS-CoV-2 variants in vitro, including Delta and Omicron
Ref: Globe Newswire | Image: Globe Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
